L35 ANSWER 9 OF 15 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:392105 HCAPLUS
DN 125:96085
TI Rhodanine derivatives useful as hypoglycemic agents and for treating **Alzheimer**'s disease
IN Bue-Valleskey, Juliana M.; Hunden, David C.; Jones, Charles D.; Panetta, Jill A.; Shaw, Walter N.
PA Lilly, Eli, and Co., USA
SO U.S., 23 pp., Cont.-in-part of U.S. Ser. No. 943, 353, abandoned.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K031-425
NCL 514369000
CC 63-6 (**Pharmaceuticals**)
Section cross-reference(s): **1**, 28
FAN.CNT 2

	PATENT NO.	KIND	DATE		APPLICATION NO.	DATE	
PI	US 5523314	A	19960604		US 1994-213651	19940316	<--
	ZA 9306492	A	19950302		ZA 1993-6492	19930902	<--
	IL 106877	A1	19980310		IL 1993-106877	19930902	<--
	IL 119119	A1	19980816		IL 1993-119119	19930902	<--
	CA 2105598	AA	19940311		CA 1993-2105598	19930907	<--
	NO 9303198	A	19940311		NO 1993-3198	19930908	<--
	AU 9346218	A1	19940317		AU 1993-46218	19930908	<--
	AU 676843	B2	19970327				
	HU 70184	A2	19950928		HU 1993-2551	19930908	<--
	RU 2131251	C1	19990610		RU 1993-51176	19930908	<--
	FI 9303946	A	19940311		FI 1993-3946	19930909	<--
	JP 06192091	A2	19940712		JP 1993-224434	19930909	<--
	CN 1091006	A	19940824		CN 1993-119081	19930909	<--
	US 5716975	A	19980210		US 1995-470822	19950606	<--
	US 5661168	A	19970826		US 1996-678015	19960710	<--
	NO 9801911	A	19940311		NO 1998-1911	19980428	<--
PRAI	US 1992-943353	B2	19920910	<--			
	IL 1993-106877	A3	19930902	<--			
	US 1994-213651	A3	19940316	<--			
	US 1994-343271	B1	19941122	<--			

OS MARPAT 125:96085
AB Rhodanine derivs. and pharmaceutical formulations thereof are claimed for treating hyperglycemia and **Alzheimer**'s disease. 5-[(4-Phenoxyphenyl)methylene]-2-thioxo-4-thiazolidinone (I) was prepared, tested for hypoglycemic activity in obese diabetic mice, and formulated in hard gelatin capsules containing I 250, starch 220, and magnesium stearate 10 mg, resp.
ST rhodanine pharmaceutical hypoglycemic **Alzheimers** disease
IT Antidiabetics and Hypoglycemics
Pharmaceutical dosage forms
(rhodanine derivs. for treating **Alzheimer**'s disease and as hypoglycemic agents)
IT **Mental** disorder
(**Alzheimer**'s disease, rhodanine derivs. for treating **Alzheimer**'s disease and as hypoglycemic agents)
IT 7467-45-0P 28824-66-0P 105769-26-4P 155670-41-0P 155670-42-1P 178735-07-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(rhodanine derivs. for treating **Alzheimer**'s disease and as hypoglycemic agents)
IT 141-84-4D, Rhodanine, derivs. 402-93-7 536-17-4 3785-78-2 3806-42-6 4703-96-2 5061-42-7 5447-37-0 5462-97-5 6301-12-8

6308-22-1 6319-47-7 6322-57-2 6326-22-3 6326-74-5 6339-79-3
21147-57-9 23622-20-0 33992-80-2 34709-44-9 37530-35-1
49581-16-0 58264-58-7 65562-51-8 67739-23-5 69505-47-1
72855-86-8 73855-59-1 73855-60-4 73855-62-6 76979-31-2 97852-70-
5 97852-85-2 97852-86-3 97852-87-4 97852-88-5 99988-44-0
99988-74-6 103987-82-2 107889-33-8 107916-92-7 110932-40-6
127378-16-9 127378-22-7 127378-26-1 132392-94-0 136433-49-3
155670-44-3 155670-45-4 155670-46-5 155670-47-6 155670-49-8
155670-50-1 155670-51-2 155670-52-3 155670-53-4 155670-54-5
155670-55-6 155670-56-7 155670-57-8 155670-58-9 155670-59-0
155670-61-4 155670-62-5 155670-69-2 155670-74-9 155670-75-0
164520-72-3 178734-94-6 178734-95-7 178734-96-8 178734-97-9
178734-98-0 178734-99-1 178735-00-7 178735-01-8 178735-02-9
178735-03-0 178735-04-1 178735-05-2 178735-06-3 **178735-08-5**
178735-09-6 178735-10-9 178735-11-0 178735-12-1 178735-13-2
178735-14-3 178735-15-4 178735-17-6
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(rhodanine derivs. for treating **Alzheimer**'s disease and as hypoglycemic agents)

IT 64-19-7, Acetic acid, reactions 67-36-7, 4-Phenoxybenzaldehyde 120-57-0, Piperonal 127-09-3, Sodium acetate 141-84-4, Rhodanine 1013-88-3, Diphenyl ketimine 4363-93-3, 4-Quinoline carboxaldehyde 5438-59-5, 3-Methoxy-4-heptoxybenzaldehyde 55512-05-5, 3-Methanesulfonamidobenzaldehyde 178735-16-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(rhodanine derivs. for treating **Alzheimer**'s disease and as hypoglycemic agents)

IT **178735-08-5**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(rhodanine derivs. for treating **Alzheimer**'s disease and as hypoglycemic agents)

RN 178735-08-5 HCAPLUS
CN 3-Thiazolidineacetic acid, 5-[[3-[(methylsulfonyl)amino]phenyl]methylene]-4-oxo-2-thioxo- (9CI) (CA INDEX NAME)



L35 ANSWER 10 OF 15 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 1993:539163 HCAPLUS
DN 119:139163
TI Synthesis and cyclooxygenase and 5-lipoxygenase inhibitory activity of some thiazolidin-4-one analogs of meclofenamic acid

AU Boschelli, Diane H.; Connor, David T.; Kuipers, Paul J.; Wright, Clifford D.
CS Dep. Chem., **Warner-Lambert** Co., Ann Arbor, MI, 48105, USA
SO Bioorganic & Medicinal Chemistry Letters (**1992**), 2(7), 705-8
CODEN: BMCLE8; ISSN: 0960-894X
DT Journal
LA English
CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): **1**
OS CASREACT 119:139163
GI



I

AB Replacement of the carboxylic acid functionality of meclofenamic acid with select heterocycles converted this cyclooxygenase (CO) inhibitor into dual inhibitors, e.g., I , of CO and 5-lipoxygenase.

ST meclofenamic acid analog thiazolidinone prepn activity; cyclooxygenase inhibitor meclofenamic acid thiazolidinone analog; lipoxygenase meclofenamic acid thiazolidinone analog

IT Molecular structure-biological activity relationship
(inflammation-inhibiting, of meclofenamic acid thiazolidinone analogs)

IT 2295-31-0, 2,4-Thiazolidinedione
RL: RCT (Reactant); RACT (Reactant or reagent)
(attempted cyclocondensation of, with aminobenzaldehyde derivative)

IT 107-95-9, β-Alanine
RL: RCT (Reactant); RACT (Reactant or reagent)
(condensation of aminobenzaldehyde derivative with rhodanine in presence of)

IT 556-90-1, Pseudothiohydantoin 4807-55-0, 3-Methylrhodanine
RL: RCT (Reactant); RACT (Reactant or reagent)
(condensation of, aminobenzaldehyde derivative)

IT 420-04-2, Cyanamide
RL: RCT (Reactant); RACT (Reactant or reagent)
(condensation of, with (methylthio)thiazole derivative)

IT 141-84-4, Rhodanine
RL: RCT (Reactant); RACT (Reactant or reagent)
(condensation of, with aminobenzaldehyde derivative)

IT 22121-59-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(cyclocondensation of, with rhodanine and derivs.)

IT 39391-18-9, Cyclooxygenase 80619-02-9, 5-Lipoxygenase
RL: PROC (Process)
(inhibition of, by meclofenamic acid thiazolidinone analogs)

IT 149703-32-2P 149703-33-3P 149703-34-4P 149703-35-5P 149703-36-6P **149703-37-7P** 149703-38-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and cyclooxygenase and lipoxygenase inhibitory activities of)

IT 644-62-2DP, Meclofenamic acid, thiazolidinone analogs

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and cyclooxygenase and lipoxygenase-inhibitory activities of)
IT 149703-39-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and hydrolysis or condensation of, with cyanamide)
IT **149703-37-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and cyclooxygenase and lipoxygenase inhibitory activities of)
RN 149703-37-7 HCAPLUS
CN 3-Thiazolidineacetic acid, 5-[[2-[(2,6-dichloro-3-methylphenyl)amino]phenyl]methylene]-4-oxo-2-thioxo- (9CI) (CA INDEX NAME)



L35 ANSWER 11 OF 15 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 1993:38921 HCAPLUS
DN 118:38921
TI Preparation of 2-substituted thiazolidinone, oxazolidinone, and imidazolidinone derivatives of fenamates as antiinflammatory agents
IN Belliotti, Thomas R.; Boschelli, Diane H.; Connor, David T.; Kostlan, Catherine R.
PA **Warner-Lambert Co., USA**
SO U.S., 12 pp.
CODEN: USXXAM
DT Patent
LA English
IC ICM C07D277-34
ICS C07D277-36; C07D277-54; A61K031-425
NCL 514364000
CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): **1**
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5143929	A	19920901	US 1991-697822	19910509 <--
PRAI US 1991-697822		19910509 <--		

OS MARPAT 118:38921
GI



I



II

AB Title compds. I [X = O, S, HN; R1 = alkyl, R2O2CCH2 wherein R2 not defined; R3-R6 = H, halo, F3C, alkyl, NC, HO, alkoxy, O2N, R8R7N wherein R7, R8 = H, alkyl, acyl, (O)nS wherein x = 0-2] and II [Y = HO, HS, H2N, R9S wherein R9 = alkyl, R10O2CCH2 wherein R10 = H, alkyl, R9(O)xS wherein w = 0-2, R10R9N, etc., (no examples or claims for oxazolidine or imidazolidinone] and salt thereof, are prepared To 2-[(2,6-dichloro-3-methylphenyl)amino]benzaldehyde at room temperature and 3-methylrhodanine in AcOH was added β-alanine and refluxed to give (Z)-I (X = S, R1 = Me, R4 = 2-Cl, R5 = 6-Cl, R6 = 3-Me) (III). In a test for antiinflaminatory activity III at 10 μM showed 100% inhibition of LTB4 formation.

ST thiazolidinone phenylaminophenylmethylene prepn antiinflammatory

IT Inflammation inhibitors
(substituted thiazolidinones)

IT 719-22-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(condensation of, with Me anthranilate)

IT 134-20-3, Methyl anthranilate
RL: RCT (Reactant); RACT (Reactant or reagent)
(condensation of, with benzoquinone derivs.)

IT 144988-03-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of thiazolidinone antiinflammatory
agents)

IT 144988-04-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)

IT 144987-93-9P 144987-94-0P 144987-95-1P 144987-96-2P 144987-97-3P
144987-98-4P 144987-99-5P 144988-00-1P 144988-01-2P
144988-02-3P 144988-05-6P **145150-70-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antiinflammatory agent)

IT 141-84-4, Rhodanine 556-90-1, Pseudothiohydantoin 4807-55-0, 3-Methylrhodanine
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of antiinflammatory agents)

IT 420-04-2, Cyanamide 22121-59-1 59304-37-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of thiazolidinone antiinflammatory agents)

IT **144988-02-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antiinflammatory agent)

RN 144988-02-3 HCAPLUS

CN 3-Thiazolidineacetic acid, 5-[[2-[(2,6-dichloro-3-methylphenyl)amino]phenyl]methylene]-4-oxo-2-thioxo-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L35 ANSWER 12 OF 15 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 1992:490273 HCAPLUS
DN 117:90273
TI Preparation of 5-benzylidenerhodanine derivatives as aldose reductase inhibitors
IN Kato, Hiroki; Sueda, Noriyoshi; Kinoshita, Nobusuke
PA Nisshin Seifun K. K., Japan
SO Jpn. Kokai Tokkyo Koho, 16 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM C07D277-36
ICS A61K031-425; A61K031-455; C07D417-12; C12N009-99
CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): **1**, 7, **63**
FAN.CNT 1

	PATENT NO.	KIND	DATE		APPLICATION NO.	DATE	
PI	JP 04099770	A2	19920331		JP 1990-217068	19900820	<--
	JP 3024781	B2	20000321				
PRAI	JP 1990-217068		19900820	<--			

OS MARPAT 117:90273
GI



I



II

AB The title compds. [I; R1 =H, HO2CCH2, alkoxycarbonylmethyl; R2 = H, halo, alkyl, alkoxy; R3 = H, alkyl, benzyl, carboxymethyl, alkoxycarbonylmethyl; R4 = alkyl, (un)substituted alkanoyl or alkenoyl, XAr; X = CO, SO2; Ar = (un)substituted Ph, naphthyl, thienyl, pyridyl, aryl; provided that when R3 = H or alkyl, R4 = group other than alkyl], useful for treatment for diabetes complications, are prepared Thus, a mixture of rhodanine 11, Me [(3-formylphenyl)(4-methoxybenzenesulfonyl)amino]acetate 12, and AcONH4 12 mmol in PhMe was refluxed for 2 h to give 75.4% title compound II. I at 10-6 M in vitro inhibited 81.4-94.2% aldose reductase. Tablets, granules, and an injection solution containing II were formulated.

ST benzylidenerhodanine prepn aldose reductase inhibitor; rhodanine benzylidene aldose reductase inhibitor; diabetes complication treatment benzylidenerhodanine

IT Antidiabetics and Hypoglycemics
(benzylidenerhodanine derivs.)

IT 142912-37-6 142912-38-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(benzylidenation by, of rhodanine)

IT 141-84-4, Rhodanine
RL: RCT (Reactant); RACT (Reactant or reagent)
(benzylidenation of, by Me (formylamino)acetate)

IT 74-88-4, Methyl iodide, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(esterification by, of (carboxymethyl)rhodanine)

IT 9028-31-3, Aldose reductase
RL: USES (Uses)
(inhibitors, benzylidenerhodanine derivs.)

IT 142911-49-7P 142911-50-0P 142911-51-1P 142911-52-2P 142911-53-3P
142911-54-4P 142911-55-5P 142911-56-6P 142911-57-7P 142911-58-8P
142911-59-9P 142911-60-2P 142911-61-3P 142911-62-4P 142911-63-5P
142911-64-6P 142911-65-7P 142911-66-8P 142911-67-9P 142911-68-0P
142911-69-1P 142911-70-4P 142911-71-5P 142911-72-6P 142911-73-7P
142911-74-8P 142911-75-9P 142911-76-0P 142911-77-1P 142911-78-2P
142911-79-3P 142911-80-6P 142911-81-7P 142911-82-8P 142911-83-9P
142911-84-0P 142911-85-1P 142911-86-2P 142911-87-3P 142911-88-4P
142911-89-5P 142911-90-8P 142911-91-9P 142911-92-0P 142911-93-1P
142911-94-2P 142911-95-3P 142911-96-4P 142911-97-5P 142911-98-6P
142911-99-7P 142912-00-3P 142912-01-4P 142912-02-5P 142912-03-6P
142912-04-7P **142912-05-8P 142912-06-9P**
142912-07-0P 142912-08-1P 142912-09-2P
142912-10-5P 142912-11-6P 142912-12-7P

142912-13-8P 142912-14-9P 142912-15-0P
142912-16-1P 142912-17-2P 142912-18-3P
142912-19-4P 142912-20-7P 142912-21-8P
142912-22-9P 142912-23-0P 142912-24-1P
142912-25-2P 142912-26-3P 142912-27-4P
142912-28-5P 142912-29-6P 142912-30-9P
142912-31-0P 142912-32-1P 142912-33-2P
142912-34-3P 142912-35-4P 142912-36-5P
142935-90-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as aldose reductase inhibitor)

IT **142912-05-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as aldose reductase inhibitor)

RN 142912-05-8 HCAPLUS

CN 3-Thiazolidineacetic acid, 5-[[3-[(2-methoxy-2-oxoethyl)[(4-methoxyphenyl)sulfonyl]amino]-4-methylphenyl]methylene]-4-oxo-2-thioxo- (9CI) (CA INDEX NAME)



L35 ANSWER 13 OF 15 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 1986:442785 HCAPLUS
DN 105:42785
TI Rhodanine derivatives
IN Niigata, Kunihiro; Kageyama, Toshiharu; Yoneda, Takashi
PA Yamanouchi Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 16 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM C07D277-36
ICS C07D417-06
ICA A61K031-425; A61K031-44; A61K031-54; C12N009-99
ICI C07D417-06, C07D207-00, C07D277-00; C07D417-06, C07D209-00, C07D277-00; C07D417-06, C07D213-00, C07D277-00; C07D417-06, C07D277-00, C07D279-00; C07D417-06, C07D311-00
CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

PI	JP 61056175	A2	19860320	JP 1984-177243	19840824 <--
PRAI	JP 1984-177243		19840824 <--		

GI



I

AB The title compds. [I; R1 = (substituted) alkyl, Ph, OH; R2 = CO2H, alkyl, adamantyl, R3X; R3 = (substituted) Ph, heterocyclyl; X = CH2, CO, bond, etc.], useful as blood platelet aggregation inhibitors (no data), were prepared Thus, condensation of rhodanine-3-acetic acid with 3-acetylindole in the presence of 1,8-diazabicyclo[5.4.0]undec-7-ene at 150° for 16 h gave I [R1 = Me, R2 = 1H-indol-3-yl].

ST rhodaninealkanoate prepn platelet aggregation inhibitor

IT Blood platelet
(aggregation of, inhibitors of, rhodaninealkanoates)

IT 5718-83-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(condensation of, with acetylindole)

IT 703-80-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(condensation of, with rhodanineacetic acid)

IT 14016-61-6P 103250-20-0P 103250-21-1P 103250-22-2P 103250-23-3P
103250-24-4P 103250-25-5P 103250-26-6P 103250-27-7P 103250-28-8P
103250-29-9P 103250-30-2P 103250-31-3P 103250-32-4P 103250-33-5P
103250-34-6P **103250-35-7P** 103250-36-8P 103250-37-9P
103250-38-0P 103250-39-1P 103250-40-4P 103250-41-5P 103250-42-6P
103250-43-7P 103250-44-8P 103250-45-9P 103250-46-0P 103250-47-1P
103250-48-2P **103250-49-3P** 103250-50-6P 103250-51-7P
103250-52-8P 103250-53-9P 103250-54-0P 103250-55-1P 103250-56-2P
103250-57-3P 103250-58-4P 103250-59-5P 103250-60-8P 103250-61-9P
103250-62-0P 103250-63-1P 103250-64-2P 103250-65-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as blood platelet aggregation inhibitor)

IT **103250-35-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as blood platelet aggregation inhibitor)

RN 103250-35-7 HCAPLUS

CN 3-Thiazolidineacetic acid, 5-[1-[4-(acetylamino)phenyl]ethylidene]-4-oxo-2-thioxo- (9CI) (CA INDEX NAME)



L35 ANSWER 14 OF 15 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 1986:129831 HCAPLUS
DN 104:129831
TI Synthesis and pharmacological properties of alkyl derivs. of 3-carboxyalkylrhodanine
AU Frankov, I. A.; Kirillov, M. V.; Sokolova, T. N.; Skupskaya, R. V.; Kharitonovich, A. N.; Chizhevskaya, I. I.
CS Med. Inst., Vitebsk, USSR
SO Khimiko-Farmatsevticheskii Zhurnal (**1985**), 19(8), 943-6
CODEN: KHFZAN; ISSN: 0023-1134
DT Journal
LA Russian
CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): **1**
OS CASREACT 104:129831
GI



I

AB The title compds. I [R = CH2CO2H, CH2CH2CO2H, 1-carboxy-2-(indol-3-yl)ethyl, CH(CO2H)(CH2)2CO2H, R1 = H, N(CH2CH2Cl)2, N(CH2CH2Br)2, NMe(CH2)2Cl] were prepared in 76-92% yields by condensation of rhodanines with p-R1C6H4CHO. I were converted to pharmaceutically acceptable salts, and I.NH4 reduced arterial blood pressure in mice from 100 ± 6 to 75 ± 4 mm at 35 mg/kg compared to dibazole which reduced pressure from 97 ± 5 to 69 ± 2 mm at 20 mg/kg.
ST antihypertensive rhodanine carboxyalkyl; thiazolone thioxobenzylidene antihypertensive
IT Antihypertensives
((carboxyalkyl)rhodanine derivs.)
IT 5718-83-2 7025-19-6 13789-81-6 16942-88-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(condensation of, with benzaldehydes)
IT 94-31-5 100-52-7, reactions 1208-03-3 27421-77-8
RL: RCT (Reactant); RACT (Reactant or reagent)

(condensation of, with rhodanine)
IT **101004-64-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antihypertensive activity of)
IT 82159-06-6P **101004-60-8P 101004-61-9P**
101004-62-0P 101004-63-1P 101004-65-3P
101004-68-6P **101018-60-4P 101018-61-5P**
101018-62-6P 101018-63-7P 101018-64-8P
101018-65-9P 101018-66-0P 101018-67-1P
101038-01-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
IT **101004-64-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antihypertensive activity of)
RN 101004-64-2 HCAPLUS
CN 3-Thiazolidinepropanoic acid, 5-[[4-[bis(2-bromoethyl)amino]phenyl]methylene]-4-oxo-2-thioxo- (9CI) (CA INDEX NAME)



L35 ANSWER 15 OF 15 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 1982:423781 HCAPLUS
DN 97:23781
TI Rhodanine derivatives and an aldose reductase inhibitor containing the rhodanine derivatives as active ingredients
IN Tadao, Tanouchi; Masanori, Kawamura; Akio, Ajima; Tetsuya, Mohri; Masaki, Hayashi; Hiroshi, Terashima; Fumio, Hirata; Takeshi, Morimura
PA Ono Pharmaceutical Co., Ltd. , Japan
SO Eur. Pat. Appl., 50 pp.
CODEN: EPXXDW
DT Patent
LA English
IC C07D277-20; C07D417-06; C07D417-14; A61K031-425
CC 28-7 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): **1, 63**
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 47109	A1	19820310	EP 1981-303816	19810821 <--
EP 47109	B1	19850102		

R: CH, DE, FR, GB, IT

JP 57040478	A2	19820306	JP 1980-115641	19800822	<--
JP 62051955	B4	19871102			
US 4464382	A	19840807	US 1981-292076	19810812	<--
JP 60156387	A2	19850816	JP 1984-255576	19841205	<--
JP 63024974	B4	19880523			
US 4791126	A	19881213	US 1987-96808	19870910	<--
US 4831045	A	19890516	US 1987-96091	19870910	<--

PRAI JP 1980-115641 19800822 <--
US 1981-292076 19810812 <--
US 1984-591753 19840321 <--

OS CASREACT 97:23781

GI



I

AB Rhodanines I [RR1 = (CH2)4, (CH2)5; R = H, R1 = cycloalkyl, cycloalkenyl, anthryl, naphthyl, Ph, substituted Ph, (un)substituted heterocyclic, (un)substituted CH:CHPh, C.tplbond.CPh; R, R1 = Ph, substituted Ph; R2 = H, alkyl, aralkyl, cycloalkyl, aryl] were prepared Thus 699 mg I (R = R2 = H, R1 = Ph) was obtained by treating 955 mg 3-carboxymethylrhodanine with 637 mg PhCHO. I have aldose reductase-inhibiting activity at 10-5-10-6M in vitro. At 100 mg/kg day for 2 wk orally I (R = R2 = H, R1 = Ph) protected streptozotocinized rats from nerve damage.

ST rhodanineacetic acid prepn diabetes neuropathy; aldose reductase inhibitor rhodanineacetate

IT Diabetes mellitus
(neuropathy of, rhodanine acetic acids in treatment of)

IT 29947-14-6P 31009-53-7P 82158-54-1P 82158-55-2P 82158-56-3P
82158-57-4P **82158-58-5P** 82158-59-6P 82158-60-9P
82158-61-0P 82158-62-1P 82158-63-2P 82158-64-3P 82158-65-4P
82158-66-5P 82158-67-6P 82158-68-7P 82158-69-8P
82158-70-1P 82158-71-2P 82158-72-3P 82158-73-4P 82158-74-5P
82158-75-6P 82158-76-7P 82158-77-8P 82158-78-9P 82158-79-0P
82158-80-3P 82158-81-4P 82158-82-5P 82158-83-6P 82158-84-7P
82158-85-8P 82158-86-9P 82158-87-0P 82158-88-1P 82158-89-2P
82158-90-5P 82158-91-6P 82158-92-7P 82158-93-8P 82158-94-9P
82158-95-0P 82158-96-1P 82158-97-2P 82158-98-3P 82158-99-4P
82159-00-0P 82159-01-1P 82159-02-2P 82159-03-3P 82159-04-4P
82159-05-5P 82159-07-7P 82159-08-8P 82159-10-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

IT 82159-06-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, esterification, and effect of, on diabetes)

IT 5718-83-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with carbonyl compds.)

IT 100-52-7, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with carboxymethylrhodanine)

IT 9028-31-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(rhodanine acetic acid as inhibitors of)

IT **82158-58-5P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 82158-58-5 HCAPLUS
CN 3-Thiazolidineacetic acid, 5-[(4-nitrophenyl)methylene]-4-oxo-2-thioxo-
(9CI) (CA INDEX NAME)



=> fil reg
FILE 'REGISTRY' ENTERED AT 07:13:42 ON 03 DEC 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 2 DEC 2003 HIGHEST RN 622845-74-3
DICTIONARY FILE UPDATES: 2 DEC 2003 HIGHEST RN 622845-74-3

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> d scan l36

L36 184 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 3-Thiazolidinepropanoic acid, 5-[[4-(dipentylamino)phenyl]methylene]-4-oxo-
2-thioxo-, (5Z)- (9CI)
MF C23 H32 N2 O3 S2

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):25

L36 184 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN Acetamide, N-[[2-[(5Z)-5-[[4-(dipentylamino)phenyl]methylene]-4-oxo-2-thioxo-3-thiazolidinyl]ethyl]sulfonyl]-2,2,2-trifluoro- (9CI)
MF C24 H32 F3 N3 O4 S3

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L36 184 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 3-Thiazolidineacetic acid, 5-[[4-(hexylmethylamino)phenyl]methylene]-4-oxo-2-thioxo-, (5Z)- (9CI)
MF C19 H24 N2 O3 S2

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L36 184 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN Benzamide, 4-fluoro-N-[[2-[(5Z)-5-[[4-(hexylmethylamino)phenyl]methylene]-4-oxo-2-thioxo-3-thiazolidinyl]ethyl]sulfonyl]- (9CI)
MF C26 H30 F N3 O4 S3

Double bond geometry as shown.

PAGE 1-A



PAGE 2-A



~~**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**~~

L36 184 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 3-Thiazolidineacetic acid, 5-[[4-(dibutylamino)phenyl]methylene]-4-oxo-2-thioxo-, (5Z)- (9CI)
MF C20 H26 N2 O3 S2

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L36 184 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN Benzamide, N-[[2-[(5Z)-5-[[4-(dibutylamino)phenyl]methylene]-4-oxo-2-thioxo-3-thiazolidinyl]ethyl]sulfonyl]-4-fluoro- (9CI)
MF C27 H32 F N3 O4 S3

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L36 184 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 3-Thiazolidineacetic acid, 5-[(1-nitro-2-naphthalenyl)methylene]-4-oxo-2-thioxo- (9CI)
MF C16 H10 N2 O5 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L36 184 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN Methanesulfonamide, 1,1,1-trifluoro-N-[2-[(5Z)-5-[[4-(hexylmethylamino)phenyl]methylene]-4-oxo-2-thioxo-3-thiazolidinyl]ethyl]- (9CI)
MF C20 H26 F3 N3 O3 S3

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L36 184 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 3-Thiazolidineacetic acid, 5-[[4-[(2-methoxy-2-oxoethyl)(3-pyridinylcarbonyl)amino]phenyl]methylene]-4-oxo-2-thioxo-, methyl ester (9CI)
MF C22 H19 N3 O6 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L36 184 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN

IN 3-Thiazolidineethanesulfonamide, 5-[[4-(hexylmethylamino)phenyl]methylene]-N-methyl-4-oxo-2-thioxo-, (5Z)- (9CI)
MF C20 H29 N3 O3 S3

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L36 184 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 3-Thiazolidineacetic acid, 5-[[4-[(2-naphthalenylsulfonyl)amino]phenyl]methylene]-4-oxo-2-thioxo- (9CI)
MF C22 H16 N2 O5 S3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L36 184 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 3-Thiazolidinebutanoic acid, 5-[[4-(4-hexyl-1-piperidinyl)phenyl]methylene]-4-oxo-2-thioxo-, (5Z)- (9CI)
MF C25 H34 N2 O3 S2

Double bond geometry as shown.

PAGE 1-A



PAGE 2-A

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L36 184 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 3-Thiazolidineacetic acid, 5-[[4-[(2-methoxy-2-oxoethyl)[(4-methoxyphenyl)sulfonyl]amino]phenyl]methylene]-4-oxo-2-thioxo- (9CI)
MF C22 H20 N2 O8 S3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L36 184 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 3-Thiazolidinebutanoic acid, 5-[[4-(4-ethyl-4-methyl-1-piperidinyl)phenyl]methylene]-4-oxo-2-thioxo-, (5Z)- (9CI)
MF C22 H28 N2 O3 S2

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L36 184 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 3-Thiazolidineacetic acid, 5-[[3-[(2-methoxy-2-oxoethyl)[(4-methoxyphenyl)sulfonyl]amino]-4-methylphenyl]methylene]-4-oxo-2-thioxo-(9CI)
MF C23 H22 N2 O8 S3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L36 184 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 3-Thiazolidineacetic acid, 4-oxo-5-[[4-(1-piperidinyl)phenyl]methylene]-2-thioxo-, (5Z)- (9CI)
MF C17 H18 N2 O3 S2

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L36 184 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 3-Thiazolidinepropanoic acid, 5-[[4-[bis(2-chloroethyl)amino]phenyl]methylene]-4-oxo-2-thioxo-, compd. with 2,2'-iminobis[ethanol] (1:1) (9CI)
MF C17 H18 Cl2 N2 O3 S2 . C4 H11 N O2

CM 1



CM 2



L36 184 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 3-Thiazolidineacetic acid, 5-[[4-(4-butyl-1-piperazinyl)phenyl]methylene]-4-oxo-2-thioxo-, (5Z)- (9CI)
MF C20 H25 N3 O3 S2

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L36 184 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 3-Thiazolidineacetic acid, 5-[(4-nitrophenyl)methylene]-4-oxo-2-thioxo-
(9CI)
MF C12 H8 N2 O5 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L36 184 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 3-Thiazolidineacetic acid, 5-[[4-(dioctylamino)phenyl]methylene]-4-oxo-2-
thioxo-, (5Z)- (9CI)
MF C28 H42 N2 O3 S2

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L36 184 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 3-Thiazolidineethanesulfonamide, N-methyl-5-[[4-(octahydro-2(1H)-isoquinolinyl)phenyl]methylene]-4-oxo-2-thioxo-, (5Z)- (9CI)
MF C22 H29 N3 O3 S3

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L36 184 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 3-Thiazolidineacetic acid, 5-[[4-(methyloctylamino)phenyl]methylene]-4-oxo-2-thioxo-, (5Z)- (9CI)
MF C21 H28 N2 O3 S2

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L36 184 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 3-Thiazolidineacetamide, N-(methylsulfonyl)-4-oxo-5-[[4-(4-propyl-1-piperidinyl)phenyl]methylene]-2-thioxo-, (5Z)- (9CI)
MF C21 H27 N3 O4 S3

Double bond geometry as shown.

PAGE 1-A



PAGE 2-A

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L36 184 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN Carbamothioic acid, bis[2-[5-[(2-hydroxy-5-nitrophenyl)methylene]-4-oxo-2-thioxo-3-thiazolidinyl]ethyl]-, O-ethyl ester (9CI)
MF C27 H23 N5 O9 S5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L36 184 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 3-Thiazolidineacetamide, 5-[[4-(dipentylamino)phenyl]methylene]-4-oxo-N-(phenylsulfonyl)-2-thioxo-, (5Z)- (9CI)
MF C28 H35 N3 O4 S3

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L36 184 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN

IN 3-Thiazolidineacetic acid, 5-[(4-nitrophenyl)methylene]-2-oxo-4-thioxo-
(9CI)
MF C12 H8 N2 O5 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> => d his

(FILE 'HOME' ENTERED AT 06:14:37 ON 03 DEC 2003)
SET COST OFF

FILE 'REGISTRY' ENTERED AT 06:14:56 ON 03 DEC 2003
L1 STR
L2 50 S L1
L3 SCR 1120 AND 1993
L4 50 S L1 AND L3
L5 9383 S L1 FUL
L6 STR L1
L7 29 S L6 SAM SUB=L5
L8 639 S L6 FUL SUB=L5
SAV L8 BOB009/A

FILE 'HCAOLD' ENTERED AT 06:58:28 ON 03 DEC 2003
L9 7 S L8
SEL AN
EDIT /AN /OREF

FILE 'HCAPLUS' ENTERED AT 06:59:02 ON 03 DEC 2003
L10 14 S E1-E7
SEL DN AN 2 4 6 8 10 12 14
L11 7 S L10 NOT E8-E28
L12 106 S L8
L13 109 S L11,L12
L14 90 S L13 AND (PD<=19990610 OR PRD<=19990610 OR AD<=19990610)
E AUGELLI/AU
L15 43 S E5,E12-E17
E SZAFRAN/AU
L16 1 S E4
E GLASE S/AU
L17 25 S E3-E8
E PURCHASE T/AU
L18 10 S E4,E5

```
L19           2 S L13 AND L15-L18
L20           4 S L13 AND (WARNER? OR LAMBERT?)/PA,CS
L21          15 S L14 AND (PHARMACEUT? OR PHARMACOL?)/SC,SX
                E IMAGING AGENT/CT
                E E4+ALL
L22           2 S L14 AND E3,E2+NT
                E E15+ALL
L23           6 S L14 AND E2+NT
                E E224+ALL
                E AMYLOID/CT
                E E3+ALL
L24           2 S L14 AND E7,E6+NT
                E E22+ALL
L25           2 S L14 AND E1
                E E4+ALL
L26           0 S L14 AND E10,E9+NT
L27           2 S L14 AND (E26+NT OR E27+NT OR E28+NT OR E29+NT OR E30+NT OR E3
L28          10 S L19,L20,L22-L27
L29           4 S L21 AND L28
L30          10 S L28,L29
L31           4 S L30 NOT (5 OR 74)/SC
L32          11 S L21 NOT L30
L33          15 S L31,L32
L34           3 S L14 AND (?ALZHEIMER? OR ?AMYLO? OR MENTAL OR COGNIT?)
L35          15 S L33,L34
                SEL HIT RN

     FILE 'REGISTRY' ENTERED AT 07:11:29 ON 03 DEC 2003
L36         184 S E1-E184

     FILE 'REGISTRY' ENTERED AT 07:12:23 ON 03 DEC 2003

     FILE 'HCAOLD' ENTERED AT 07:12:35 ON 03 DEC 2003

     FILE 'HCAPLUS' ENTERED AT 07:12:52 ON 03 DEC 2003

     FILE 'REGISTRY' ENTERED AT 07:13:42 ON 03 DEC 2003
                SAV L36 BOB009A/A

=>
```